SEPTEMBER 12, 2024
Opioid misuse and overdose in the aging population needs increased attention
News & Insights
SEPTEMBER 3, 2024
Orexo to attend the Pareto Securities 15th Annual Healthcare Conference on Sep. 19
JULY 17, 2024
Orexo Q2 2024 Interim Report
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.
Development pipeline targeting large medical needs
ESG sustainable investing
Read all documents related to the refinancing of the existing bond - MARCH 2024
Key financial figures
Group net revenue
615 MSEK
Last Twelve Months, Q323-Q224
Group EBITDA
22 MSEK
Last Twelve Months, Q323-Q224
US Commercial segment EBIT
145 MSEK
Last Twelve Months, Q323-Q224
Cash position
140 MSEK
Q224